Singh Sahib, Garg Lohit, Kanjwal Mohammed Y, Bliden Kevin, Tantry Udaya S, Gurbel Paul A, Alraies M Chadi, Damluji Abdulla A
Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.
Division of Cardiology, University of Colorado, Aurora, CO 80045, USA.
J Clin Med. 2024 Dec 17;13(24):7700. doi: 10.3390/jcm13247700.
Atrial fibrillation (AF) is the leading cause of arrhythmia-related morbidity and mortality. Recurrent symptoms, hospitalizations, and cost burden to patients have necessitated treatments beyond antiarrhythmic drugs (AADs) for patients with AF. Catheter ablation has proven to be effective over medical therapy alone; however the recurrence rates for atrial tachyarrhythmias post-ablation remain significant, particularly in patients with persistent and long-standing persistent AF. Hence, new techniques for catheter ablation have arisen, such as non-thermal energy sources, novel catheters, electroanatomical mapping, and ablation of additional targets. In this review, we discuss the recent advances in the field of catheter ablation, including newer modalities for the prevention of adverse events and future perspectives.
心房颤动（AF）是心律失常相关发病和死亡的主要原因。复发性症状、住院治疗以及患者的费用负担使得房颤患者除了使用抗心律失常药物（AADs）之外还需要其他治疗方法。导管消融已被证明比单纯药物治疗更有效；然而，消融术后房性快速心律失常的复发率仍然很高，尤其是在持续性和长期持续性房颤患者中。因此，出现了新的导管消融技术，如非热能来源、新型导管、电解剖标测以及额外靶点的消融。在本综述中，我们讨论了导管消融领域的最新进展，包括预防不良事件的新方法和未来展望。
